Abstract: Advanced glycation end products (AGEs) are involved in the occurrence of vascular complications in diabetes. The present study was undertaken to investigate the level of low-molecular weight products of AGEs (LMW-AGEs) in relation to microvascular complications in type 1 diabetes, and the possible relationship with nitric oxide (NO) as a marker of endothelial function. Patients with normal renal function (NRF) were classified into two groups: (1) without, and (2) with diabetic neuropathy; and patients with renal impairment also into two groups: (3) diabetic renal disease, and (4) end-stage renal disease. The fluorescence of LMW-AGEs and measurement of NO metabolites was assessed in 277 serum samples. In addition, multiple regression analysis was performed. In group 1, LMW-AGEs level (9.3±1.1 AF%) was higher than in the control group (2.4±0.3 AF%). A trend in the increase of LMW-AGEs with neuropathy (29.7±5.5 AF%, group 2), and further with renal impairment (47.0±8.0, group 3 and 137.8±25.5 AF%, group 4), was observed. In multivariate regression analysis LMW-AGEs were associated with NO metabolites in group 2. In NRF patients, diabetic neuropathy was significantly correlated with LMW-AGEs and NO metabolites, independently of serum creatinine and duration of diabetes. This relationship suggests that the NO and LMW-AGEs' actions (possibly synergistic) in endothelial activation possess a role in the initiation and development of diabetic microvascular complications.
Introduction
Advanced glycation end products (AGEs) play an important role in the progression of chronic diabetic complications (such as neuropathy) [1] . Indeed, they accumulate both in the circulation and in tissues as a result of their increased production, and are only slowly eliminated during renal dysfunction [2] . As such, circulating AGE modified proteins are considered to be a heterogeneous class of potentially toxic substances that can affect different ranges of both cells and tissues.
These circulating low molecular weight (LMW) AGE species (LMW-AGEs), considered the "second generation" of AGEs [3] , are the incomplete degradation products of tissue-bound or circulating AGEs, generated via the activity of extracellular proteolysis systems [4] . LMW-AGEs react with susceptible proteins from the walls of blood vessels and contribute to the development of diabetic chronic complications [3] . Recent studies have found that an increase in accumulation of fluorescent Correlation of low molecular weight advanced glycation end products and nitric oxide metabolites with chronic complications in type 1 diabetic patients products (in skin) even before the clinic manifestation of diabetic neuropathy present [5] . Several reports have indicated that LMW-AGEs correlate with progressive renal injury in human type 1 and type 2 diabetes [6, 7] , but not with diabetes per se [8] . This suggests that LMWAGEs may be used as a marker for the prediction of diabetic renal disease development, and the evaluation of its severity [3] , from incipient renal disease towards end-stage renal disease [9] .
Nitric oxide (NO) plays an important role in the homeostatic vasodilatation and regulation of blood flow. Preservation of normal endothelial function depends on NO bioavailability. However, the elevated NO production stimulated by insulin in diabetes, and the excess of NO released, causes endothelial dysfunction and further vascular complications. It has recently been presented that increased plasma concentration of NO metabolites (the stable end-product nitrite/nitrate, NOx) in patients with type 2 diabetes may be associated with the pathogenesis of diabetic retinopathy [10] and neuropathy (by peripheral nerve damage) [11] . It has also been shown that the synergistic actions of NO and AGEs account for the irreversible nitrergic nerve degeneration in diabetes [12] .
In a study by Sharp et al. [6] it was demonstrated that there is an increase of LMW-AGEs level in diabetic patients with minimal renal disturbance, or with serum creatinine levels in normal range. However, to date there is only one report focused on the relationship of AGEs with diabetic neuropathy [5] . Therefore, the present study addresses two important questions: (i) whether accumulation of LMW-AGEs contributes to the pathogenesis of microvascular complications in type 1 diabetic patients, and (ii) if there is a correlation between LMW-AGEs and circulating NO metabolites (a surrogate indicator for circulating NO as marker of endothelial function). We have analyzed the levels of LMW-AGEs and NOx according to the presence or absence of renal impairment, since the association of LMW-AGEs with renal disease was reported previously, yet no data is currently available regarding the association with other chronic diabetic complications.
Experimental Procedures

Characterization of subjects
Diabetic patients (n=211), all Romanian Caucasians aged ≥ 16 years, were investigated in the clinical departments of the Institute of Diabetes, Nutrition and Metabolic Diseases "Prof. NC Paulescu" (Bucharest, Romania). Type 1 diabetes was defined according to the criteria used in the EURODIAB study [13] . The patients were characterized by an acute onset of diabetes, with the necessity to start insulin therapy within one month postdiagnosis of the disease, and requiring the continuous use of insulin without interruption of treatment for more than 6-12 months.
Clinical characteristics were recorded. The body mass index (BMI) was calculated as the weight (Kg) divided by the square of height (m 2 ). Systolic and diastolic blood pressures (BP) were recorded by means of three measurements at five minutes intervals, made in the supine position. Hypertension (HT) was defined as a systolic BP>140 mmHg and/or diastolic BP >90 mm Hg (in untreated patients), or current antihypertensive treatment. The diagnosis of diabetic neuropathy and retinopathy was based on the presence of diagnostic criteria used in the EURODIAB Study [13] . The presence of impaired renal function was assessed by calculating creatinine clearance. The presence of end-stage renal disease, and the type of renal replacement therapy (peritoneal dialysis and hemodialysis), were recorded in this group. Creatinine clearance (Cl Cr , ml/min) was estimated using Cockcroft-Gault formula [(140-age) x weight]/72 x serum creatinine (S Cr , mg/100 ml). For women, the value given by this equation was multiplied by 0.85 [14] . Total cholesterol (T-Cho), triglycerides (Tg), and hemoglobin (Hb A C1 ) were determined for all patients in blood samples collected after an overnight fast (at least 12 h). Aliquots of serum samples were stored frozen at -70 o C until used for LMW-AGEs analysis. Non-diabetic age-matched subjects (n= 66) were employed as controls, and their sera was analyzed for circulating LMW-AGEs values. The research was in agreement with national guidelines and institutional policies, and informed consent was obtained from all subjects involved in this study.
LMW-AGEs analysis
The fluorescent measurement of serum LMW-AGEs was conducted as previously described [6] . Briefly, aliquots (20 μl) of sera were precipitated with trichloracetic acid (0.144 M, final concentration) with lipids then extracted using chloroform (100 μl). Fluorescence (excitation at 370 nm and emission at 440 nm) of LMWAGEs was determined in the collected aqueous layers of microfuged samples. For LMW-AGEs standard prepared human albumin-AGEs were first digested with 0.4 U proteinase K, and then treated as serum samples. For both the standard and serum samples the relative fluorescence/mg peptide/ml (absolute fluorescence, AF) was calculated. LMW-AGEs standard (1 mg/ml) gave 187 AF. The data were reported as AF% of the LMWAGEs standard.
Measurement of serum NO metabolites
The stable end-product nitrite/nitrate (NOx), as an expression of NO availability was determined as a marker of endothelial function. Measurements of serum NOx as total nitrite concentration was performed with Griess reagents, after incubation with nitrate reductase for enzymatic conversion. Sodium nitrite standard solution was used for the calibration curve. The yield of nitrite was expressed as micromoles / Liter (µmol/L) [15] .
Statistical analysis
The baseline parameters of the diabetic patients were compared with the controls using a one-way ANOVA test. The relationship between serum LMW-AGE and circulating NO metabolites, as well as baseline parameters, was analyzed by Spearman correlation coefficient; and then by multiple linear regression for continuous variables, with LMW-AGEs as the dependent variable. Multivariate binary logistic regression analysis in a sex-adjusted model was used with diabetic microangiopathy as dependent variable. All parameters entered in the regression analysis were log transformed for normal distribution. A significant P value was considered to be 0.05 or less, and all of the data was analyzed using SPSS 10.0 software.
Results
Subject characteristics from the presented study are summarized in Table 1 . Compared with the control groups, significant differences (P<0.001) were found in diabetic patient groups for glucose, triglycerides, systolic and diastolic BP, and serum creatinine. Diabetic patients were separated according to Cl Cr values, into patients with normal renal function (NRF; Cl Cr ≥ 80 mL/min) and renal impairment (Cl Cr <80 mL/min). When these two groups were compared, most of the basic characteristics were not different, except for the duration of diabetes, and serum creatinine (P<0.001).
The prevalence of microvascular (neuropathy and retinopathy) complications and hypertension was significantly elevated (P<0.001) in patients with renal impairment as compared with those with normal kidney function. Less than 5% of patients presented ischemic heart disease.
The LMW-AGEs concentration was significantly higher (P<0.001) in the whole group of patients as compared with non-diabetic subjects, as well as in patients with renal impairment as compared with NRF subjects (Table 1) .
To analyze the circulating LMW-AGEs as a function of vascular complications NRF patients were categorized as not having any microvascular complications (group 1), or having neuropathy and eventually also retinopathy (group 2). Patients with renal impairment were separated into: group 3. having incipient or mild diabetic renal Correlation of low molecular weight advanced glycation end products and nitric oxide metabolites with chronic complications in type 1 diabetic patients disease; or group 4, having end-stage renal disease requiring replacement therapy. The prevalence of microangiopathies increased progressively from group 2, where all the patients had diabetic neuropathy and 54.5% retinopathy, towards group 3 and 4 with renal impairment. The proportion of neuropathy and retinopathy in the latter two groups was 81.3% and 73.3% in group 3, and 95.2% and 92.9% in group 4, respectively.
There was a significant increase in LMW-AGEs (9.28±1.05 AF%) in group 1 (P<0.001) as compared with the control group (2.43±0.3). Serum LMW-AGEs showed a significant trend toward accumulation with the presence of microangiopathy, from 29.74 ± 5.5 AF% in group 2, to 46.98 ± 8.0 AF% in group 3. The highest level of LMW-AGEs (137.84 ± 25.5 AF%) was found in group 4, which was significantly higher (P<0.001) than in group 3 ( Figure 1) .
We further assessed whether clinical factors affect serum LMW-AGEs levels. Linear regression analysis (a sex adjusted model) with serum LMW-AGEs as the dependent variable against log transformed parameters (age, duration of diabetes, FBG, HgA1C, Tg, T-Cho, S Cr , Cl Cr ) showed a significant relationship (F=74.7; r 2 =0.36) with serum creatinine (standardized β=-0.72; P=0.015) and the duration of diabetes (standardized β=0.45; P=0.036) in group 1, total cholesterol (F=8.3; r 2 = 0.68, standardized β=0.87; P=0.045) in group 2 and serum creatinine (F=8.6; r 2 =0.63; standardized β=0.80; P=0.032) in group 3. In group 4 the association was significant (F=7.9; r 2 =0.86) for creatinine clearance (standardized β=-1.09; P=0.032) and duration of diabetes (standardized β=-0.54; P=0.038). There was no significant relationship of LMW-AGEs with any of the parameters in control patients. By adding systolic and diastolic BP into the equation, the relationship of LMW-AGEs with serum creatinine remained significant (standardized β=3.42; P=0.021) in group 3, only.
Knowing that patients with diabetes mellitus exhibit nitric oxide-mediated vasodilatation the measurement of serum NOx was performed as an expression of NO availability. There was a tendency towards increased NOx concentrations with vascular complications; from 32.98 ± 4.49 µmol/L in group 1 without any clinically manifested microangiopathies, to 48.22 ± 4.1 µmol/L in group 2 with diabetic neuropathy. The highest levels were found in patients with renal impairment, 52.15 ± 5.61 µmol/L in group 3, and 60.47 ± 10.31 µmol/L in group 4. ANOVA tests revealed a significantly increased NOx concentration in group 1 (F=10.0, P=0.002) as compared with the control (20.83 ± 1.84), and in group 2 (F=4.84, P=0.031) as compared with group 1.
Linear regression analysis showed a significant association between LMW-AGEs and NOx in NRF patients and the whole group of diabetic patients; however from the individual groups the association was Table 2 . Relationship between LMW-AGEs and NO metabolites. The data is expressed as Mean ± SEM; Beta, coefficient; P, significance; Adjusted* for age, gender, FBG, T-Cho, Tg, and the presence of retinopathy, neuropathy and renal disease (for 1 to 3 and 1 to 4).
significant only in group 2 ( Table 2 ). The relationship remained significant when adjusted for age, gender, FBG, T-Cho, Tg, the presence of retinopathy, neuropathy and renal disease (for groups with renal impairment).
In patients with normal renal function, multivariate logistic regression analysis showed in a sex-adjusted model a significant correlation of diabetic neuropathy with LMW-AGEs (OR=1.8; 95% CI=1.11-2.93) and NOx (OR=1.74; 95% CI=1.06-2.83). The relationship remained significant in the presence of duration of diabetes, serum creatinine, age, blood glucose, systolic and diastolic blood pressure (Table 3) . However, in the whole group of patients diabetic nephropathy was significantly (P=0.009) associated with LMW-AGEs (OR=2.58; 95% CI=1.82-3.67), as expected, but not with NOx. The relationship remained significant in the presence of serum creatinine (Table 4 ).
Discussion
The present study showed that the level of serum LMW-AGEs was significantly elevated in our whole group of patients with type 1 diabetes when compared with healthy subjects, in agreement with observations previously reported by others [2, 6, 8] . Our data also confirmed previous reports [3, 7, 8, 16] showing high accumulation of circulating LMW-AGEs in diabetic patients with nephropathy and end stage renal disease. Conversely, other reports found increased levels of AGE peptides in patients with minimal renal disturbance, or with normoalbuminuria, indicating that AGE peptides are also part of the diabetes state, and are not simply a function of renal impairment [16] . We did not find reported data on the involvement of AGE peptides in the pathogenesis of other microvascular complications before the occurrence of diabetic nephropathy. This study was particularly focused on the involvement of LMW-AGEs in the initiation and development of diabetic neuropathy and retinopathy in patients with normal renal function. The careful monitoring of serum LMWAGEs, indicated that in these patients (groups 1 and 2) separated according to the presence or absence of microangiopathy, LMW-AGEs levels remained significantly high even in the absence of diabetic neuropathy. Recent reports [5] have found increased accumulation of AGE products (in skin) before clinic manifestation of diabetic neuropathy.
The progression of diabetes predisposes patients to chronic complications affecting the blood vessels, eyes, nerves and kidneys. We found in patients with diabetic neuropathy and normal renal function a threefold higher concentration of LMW-AGEs than in diabetic patients with no complications. These results might suggest the independent contribution of LMW-AGEs to the initiation of diabetes-associated microangiopathy (i.e. neuropathy) even before clinical manifested diabetic renal disease. Other reports have not found significant increased fluorescent AGE [6, 14] in the presence of clinical diabetic complications (retinopathy, neuropathy).
Diabetic neuropathy, a life-threatening complication, is based on the impairment of blood flow at the level Table 3 . Relationship of diabetic neuropathy with LMW-AGEs and NO metabolites in a sex-adjusted model for patients with normal renal function.
Other variables entered into the equation (age, blood glucose, systolic and diastolic blood pressure) were not significantly correlated with neuropathy; OR, Exp (B); P, significance; 95.0% C.I., confidence interval for Exp (B). Correlation of low molecular weight advanced glycation end products and nitric oxide metabolites with chronic complications in type 1 diabetic patients of both peripheral and autonomic nerves. Proteins of the nerves are glycated and may facilitate endoneural vascular dysfunction, leading to microangiopathy in peripheral nerves [1] . However, nitric oxide participates in critical actions involving several aspects of peripheral nerve function and disease. By its actions on vasa nervorum (the blood supply to nerves) it participates in microvascular changes following injury. Excessive local levels of NO may also contribute to diabetic neuropathy [11] . Our results showed an association of circulating NO metabolites with LMW-AGEs in the present of other cofounders (see Table 3 ); this relationship remained significant by adding diabetic neuropathy into the equation. To our knowledge, this is the first study that shows a relationship of LMW-AGEs with nitric oxide, and their actions might account for the pathogenesis of diabetic neuropathy. Controversially, in patients with renal impairment diabetic nephropathy was associated only with LMW-AGEs, without any influence of NOx.
Variables
Taken together, our observations indicate that accumulation of LMW-AGEs is increased with the initiation and progression of microvascular dysfunction in type 1 diabetic patients, from the development of neuropathy (and retinopathy) towards the presence of late complications like renal disease and end stage renal disease. We found a correlation between LMWAGEs and NO metabolites (a substitute for NO, as an endothelial marker) in the presence of neuropathy in diabetic patients with normal renal function but not in those with renal impairment. These data may suggest that the actions (possibly synergistically) of NO and LMW-AGEs in the endothelial activation have a role in the initiation and development of microvascular complications associated with diabetes mellitus.
